Document:

EX-10.11

 Exhibit 10.11 

EXECUTION COPY 
 AMENDED 11-18-2013

 August 2, 2013 
 Mrs. Alane Barnes 

1929 Brassfield Rd. 
 Raleigh, NC 27614 

abarnes@biocryst.com 
 Dear Mrs. Barnes: 

On behalf of BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst” or the “Company”), we are pleased to
extend this employment agreement to you as Vice President & General Counsel. We, along with the other members of the Company’s Board of Directors (the “Board”), and the Company’s management team, continue to be very
impressed with you and what you bring to the Company. We believe that with your background, you will continue to make significant contributions to the success of the Company. 

This letter agreement (the “Agreement”) will serve to confirm our agreement with respect to the terms and conditions of your
employment. 
 1. Term of Employment. Subject to the terms and conditions of this Agreement, BioCryst hereby employs Alane Barnes (the
“Employee”), with an effective hire date of September 18, 2006 as Vice President & General Counsel . Employee shall maintain employment at the Company’s Durham, North Carolina . The Employee shall not, during the term of
his employment, engage in any other business activity that would interfere with, or prevent him from carrying out, his duties and responsibilities under this Agreement. BioCryst hereby agrees and acknowledges that any compensation which the Employee
receives from participation in such allowable activities shall be outside the scope of this Agreement and in addition to any compensation received hereunder. The term of employment of Employee under this Agreement shall commence as of July 29,
2013, and shall terminate on July 29 , 2016 unless earlier terminated in accordance with the provisions of paragraph 4 hereof. In the event Employee is retained by the Company as Vice President & General Counsel past July 29
, 2016, the terms of his employment shall continue to be governed by this Agreement unless otherwise provided by the Board. 
 2. Basic Full-Time
Compensation and Benefits. 
 (a) As basic compensation for services rendered under this Agreement, Employee shall be
entitled to receive from BioCryst, a salary of $19,309.08 per month ($231,709 per 

 Mrs. Alane Barnes 

August 1, 2013 
  Page
 2
 
  

 
annum) payable in bi-monthly payments for each calendar month during the term of this Agreement, beginning July 29 , 2013. This salary will be reviewed annually by the Board of Directors and may
be raised at the discretion of the Board. 
 (b) In addition to the basic compensation set forth in (a) above, Employee
shall be eligible to earn a cash bonus, payable as soon as reasonably practicable in the calendar year following each calendar year during the term of this Agreement, based on the Company’s achievement of performance related goals proposed by
management and approved by the Board for the Company’s applicable fiscal year (the “Fiscal Year”). The bonus actually earned, if any, shall be based on a target amount equal to 30% of the base compensation earned by executive during
such Fiscal Year (the “Target Amount”), and shall be pro-rated based on the degree to which the performance goals have been achieved, subject to a minimum level of achievement proposed by management and approved by the Board. The Target
Amount for the 2013 Fiscal Year shall be prorated based on Employee’s base compensation earned during 2013. The Board may, in its discretion, approve a bonus in excess of the Target Amount if the performance goals have been exceeded. Employee
must be employed through April 1, of the next succeeding Fiscal Year in order to receive the annual bonus for each Fiscal Year. 

(c) In addition to the basic compensation set forth in (a) and (b) above, Employee shall be entitled to receive such
other benefits and perquisites provided to other executive officers of BioCryst which benefits may include, without limitation, reasonable vacation (currently 4 weeks), sick leave, medical benefits, life insurance, and participation in profit
sharing or retirement plans. 
 (d) In addition to the compensation set forth in paragraphs 2(a), (b) and
(c) above, the Board of Directors of BioCryst may from time to time, in its discretion, also grant such other cash or stock bonuses to the Employee either as an award or as an incentive as it shall deem desirable or appropriate. 

3. Performance Based Equity Awards. 
 In connection with
Employee’s execution of this Agreement, Employee shall be eligible for equity incentive awards as follows: 
 (a) As
part of the BioCryst Pharmaceuticals Performance Management & Compensation Planning program, you will be eligible for additional long term equity awards (mix of stock options and restricted stock awards). The actual equity award pool will
be determined each year, with individual equity awards based on Employee performance assessment and results against individual objectives. All equity awards will reflect the specific guidelines of the program, are subject to approval each year by
the Compensation Committee of the Board and subject to the requirements of state and federal laws. 

 Mrs. Alane Barnes 

August 1, 2013 
  Page
 3
 
  

 (b) The parties intend for the Option to qualify as “incentive stock
options,” as that term is defined in Section 422 of the Internal Revenue Code of 1986, as amended (“Section 422”) to the fullest extent possible. The parties understand that the portion of the Option, together with the portion of
any other incentive stock option granted by BioCryst and its parent and subsidiary corporations, if any, which may become exercisable in any year in excess of an aggregate of $100,000 fair market value, determined as of the date the Option or such
other Option, as the case may be, was granted, and may not be treated as an incentive stock option under Section 422. 

(c) The award set forth in paragraph 3(a) above will vest, contingent on Employee’s continued provision of services to the
Company on each respective vesting date, over a period of 4 years as follows: The Option will initially become exercisable for 25% of the Optioned Shares upon Optionee’s completion of twelve (12) months of Service (as defined in the
Standard Stock Option Agreement) measured from the Grant Date and will become exercisable for the balance of the Optioned Shares at the rate of 25% of the Optioned Shares upon Optionee’s completion of each additional year of Service measured
from the first anniversary of the Grant Date for the following three years until fully vested on the fourth anniversary of the grant. 

(d) The stock option and restricted stock awards set forth in paragraph 3(a ) above shall be granted under and subject to the
terms of the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (the “Stock Incentive Plan”). All awards shall be subject to the terms of specific award agreements between the Employee and the Company, which Employee will be required to
execute as a condition of the grants. 
 4. Termination. 

(a) If Employee’s employment is terminated as a result of (i) the expiration of the stated term of this Agreement,
(ii) the Employee’s resignation, (iii) the Employee’s death, (iv) by the Company for Cause, or (v) by the Company as a result of Disability, Employee will receive base salary, as well as any accrued but unused vacation
(if applicable) and other compensation, earned through the effective termination date, and no additional compensation, except as set forth in Section 4(d) below. 

For all purposes under this Agreement, a termination for “Cause” shall mean a determination by the Board that
Employee’s employment be terminated for any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, 

 Mrs. Alane Barnes 

August 1, 2013 
  Page
 4
 
  

 
standards or regulations of Company; (ii) a violation of a federal or state law or regulation applicable to the business of the Company; (iii) conviction or plea of no contest to a
felony under the laws of the United States or any State; (iv) fraud or misappropriation of property belonging to the Company or its affiliates; (v) a breach in any material respect of the terms of any confidentiality, invention assignment
or proprietary information agreement with the Company or with a former employer, (vi) failure to satisfactorily perform Employee’s duties after having received written notice of such failure and at least thirty (30) days to cure such
failure, or (vii) misconduct or gross negligence in connection with the performance of Employee’s duties. 

“Disability” shall mean the inability of Employee to perform his duties hereunder by reason of physical or mental
incapacity for ninety (90) days, whether consecutive or not, during any consecutive twelve (12) month period. 

(b) If the Company terminates Employee’s employment without Cause, it shall provide written notice of termination to
Employee, along with any base salary and accrued but unused vacation or other compensation earned through the effective termination date, and, conditioned on Employee (a) signing and not revoking a release of any and all claims, in a form
prescribed by the Company, and (b) returning to the Company all of its property and confidential information that is in Employee’s possession, Employee will receive the following: (i) continuation of base salary for 1 year beyond the
effective termination date, payable in accordance with the regular payroll practices of the Company; and (ii) if Employee elects to continue health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(“COBRA”) following termination of employment, the Company shall pay the monthly premium under COBRA until the earlier of (x) 12 months following the effective termination date, or (y) the date upon which Employee commences
employment with an entity other than the Company. Employee will notify the Company in writing within 5 days of your receipt of an offer of employment with any entity other than the Company, and will accordingly identify the date upon which you will
commence employment in such writing. 
 (c) If, during Employee’s employment with the Company, there is a Change of
Control, all equity awards granted to Employee under paragraph 3 and otherwise shall vest in full. In addition, if the Company terminates Employee’s employment without Cause or Employee is Constructively Terminated within 6 months of the Change
in Control, then Employee will be eligible to receive the benefits provided in paragraph 4(b), under the terms and conditions set forth in that paragraph. 

“Change of Control” shall be defined as (i) a merger or consolidation in which the Company is not the surviving
entity, except for a transaction the principal purpose of which is 

 Mrs. Alane Barnes 

August 1, 2013 
  Page
 5
 
  

 
to change the State of the Company’s incorporation; (ii) the sale, transfer or other disposition of all or substantially all of the assets of the Company in liquidation or dissolution
of the Company; (iii) any reverse merger in which the Company is the surviving entity but in which securities possessing more than fifty percent (50%) of the total combined voting power of the Company’s outstanding securities are
transferred to a person or persons different from the persons holding those securities immediately prior to such merger; (iv) any person or related group of persons (other than the Company or a person that directly or indirectly controls, is
controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined
voting power of the Company’s outstanding securities pursuant to a tender or exchange offer made directly to the Company’s stockholders; or (v) a change in the composition of the Board over a period of twenty-four
(24) consecutive months or less such that a majority of the Board members (rounded up to the next whole number) ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have
been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least two-thirds of the Board members described in clause (A) who were still in
office at the time such election or nomination was approved by the Board. 
 “Constructive Termination” shall mean
a resignation of employment within 30 days of the occurrence of any of the following events which occurs within 6 months following a Change of Control: (i) a material reduction in Employee’s responsibilities; (ii) a material reduction
in Employee’s base salary, unless such reduction is comparable in percentage to, and is part of, a reduction in the base salary of all executive officers of the Company; or (iii) a relocation of Employee’s principal office to a
location more than 50 miles from the location of Employee’s principal office immediately preceding a Change of Control. 

(d) If (i) Employee remains an employee of the Company after the expiration of the three year term of this Agreement; and
(ii) within 6 months thereafter, Employee resigns as a result of a material and adverse change in the Company’s business, then Employee shall be entitled to receive the severance benefits on the terms and conditions specified in paragraph
4(b) above. 
 (e) In the event (i) any payments described in paragraphs 4(b), (c) or (d) above would be
“deferred compensation” subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”); and (ii) Employee is a “specified employee” (as defined in Code Section 409A(2)(B)(i)), such
payments shall, to the extent required by Code Section 409A, be delayed for the minimum period and in the minimum manner necessary to avoid the imposition of the tax required by Code Section 409A. 

 Mrs. Alane Barnes 

August 1, 2013 
  Page
 6
 
  

 5. Non-Competition; Proprietary Information and Inventions. 

(a) Proprietary Information and Inventions Agreement. As a condition precedent to the employment of Employee by the
Company, Employee shall execute the Company’s standard Proprietary Information and Inventions Agreement, attached hereto as Exhibit A. 

(b) Non-Competition Agreement. The Employee agrees that for one (1) year following the termination of this
Agreement by reason of the voluntary termination by the Employee, without cause on the part of BioCryst, the Employee shall not become the Vice President Drug Discovery or become a key executive of another for-profit business enterprise whose
activities are at such time directly competitive with BioCryst. 
 (c) Equitable Remedies. Employee acknowledges and
recognizes that a violation of this paragraph by Employee may cause irreparable and substantial damage and harm to BioCryst or its affiliates, could constitute a failure of consideration, and that money damages will not provide a full remedy for
BioCryst for such violations. Employee agrees that in the event of his breach of this paragraph, BioCryst will be entitled, if it so elects, to institute and prosecute proceedings at law or in equity to obtain damages with respect to such breach, to
enforce the specific performance of this paragraph by Employee, and to enjoin Employee from engaging in any activity in violation hereof. 
 6.
Miscellaneous. 
 (a) Entire Agreement. This Agreement, including the exhibits hereto, constitutes the entire
agreement between the parties relating to the employment of the Employee by BioCryst and there are no terms relating to such employment other than those contained in this Agreement. No modification or variation hereof shall be deemed valid unless in
writing and signed by the parties hereto. No waiver by either party of any provision or condition of this Agreement shall be deemed a waiver of similar or dissimilar provisions or conditions at any time. 

(b) Assignability. This Agreement may not be assigned without prior written consent of the parties hereto. To the extent
allowable pursuant to this Agreement, this Agreement shall be binding upon and shall inure to the benefit of each of the parties hereto and their respective executors, administrators, personal representatives, heirs, successors and assigns. 

 Mrs. Alane Barnes 

August 1, 2013 
  Page
 7
 
  

 (c) Notices. Any notice or other communication given or rendered
hereunder by any party hereto shall be in writing and delivered personally or sent by registered or certified mail, postage prepaid, at the respective addresses of the parties hereto as set forth below. 

(d) Captions. The section headings contained herein are inserted only as a matter of convenience and reference and in no
way define, limit or describe the scope of this Agreement or the intent of any provision hereof. 
 (e) Taxes. All
amounts to be paid to Employee hereunder are in the nature of compensation for Employee’s employment by BioCryst, and shall be subject to withholding, income, occupation and payroll taxes and other charges applicable to such compensation. 

(f) Governing Law. This Agreement is made and shall be governed by and construed in accordance with the laws of the
State of Alabama without respect to its conflicts of law principles. 
 (g) Date. This Agreement is dated as of
July 29, 2013. 

 Mrs. Alane Barnes 

August 1, 2013 
  Page
 8
 
  

 If the foregoing correctly sets forth our understanding, please signify your acceptance of
such terms by executing this Agreement, thereby signifying your assent, as indicated below. 
  

			
	Yours very truly,
	
	BIOCRYST PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Jon Stonehouse

		 	Jon Stonehouse
		 	Chief Executive Officer
	
	Address:
	4505 Emperor Blvd., Suite 200
	Durham, NC 27703

 Cc: Robert C. Stoner, Vice President Human
Resources 
 AMENDED, AGREED AND ACCEPTED, as of this 18th day of November, 2013. 

 

			
	 /s/ Alane Barnes

	Alane Barnes
	
	Address:
	
	1929 Brassfield Rd.
	Raleigh, NC 27614

 EXECUTION COPY 

Exhibit A 
 (Proprietary
Information and Inventions Agreement) 
 EMPLOYEE’S PROPRIETARY INFORMATION AND INVENTIONS 

AGREEMENT 
 I, Alane Barnes, recognize that
BioCryst Pharmaceuticals, Inc., a Delaware corporation (hereinafter the “Company”, is engaged in a continuous program of research, development, and product; on respecting its business, present and future, including fields generally related
to its business. 
 I understand that: 
 A. As
part of my employment by the Company I will faithfully and diligently serve and endeavor to further and safeguard the interests of the Company and I recognize that I am expected to make new contributions and inventions of value to the Company; 

B. My employment creates a relationship of confidence and trust between me and the Company with respect to any information: 

1. Applicable to the business of the Company: or 

2. Applicable to the business of any client or customer of the Company which may be made known to me by the Company or by any client or
customer of Company or learned by me during the period of my employment. 
 C. The Company possesses and will continue to possess information that has been
created, discovered, developed, or otherwise become known to the Company (including without limitation information created, discovered, developed, or made known by me during the period of or arising out of my employment by the Company) and/or in
which property rights have been assigned or otherwise conveyed to the Company, which information has commercial value in the business in which the Company is or may be engaged. All of the aforementioned information is hereinafter called
“Proprietary Information.” By way of illustration, but not limitation Proprietary Information includes trade secrets, processes, formulas, data and know-how, improvements, inventions, techniques, marketing plans, strategies, forecasts, and
customer lists. 
 In consideration of my employment or continued employment, as the case may be, by the Company and the compensation
received by me from the Company from time to time. I hereby agree as follows: 
 1. All Proprietary Information shall be the sole property of the Company
and its assigns, and the Company and its assigns shall be the sole owner of all patents and other rights, title and interest in connection therewith. I hereby assign to the Company any and all rights I may have or acquire in such Proprietary
Information and/or patents. At all times, both during my employment by the Company and after its termination, I will keep in confidence and trust all Proprietary Information, and I will not use or disclose any Proprietary Information or anything
relating to it without the prior written consent of the Company, except as may be necessary in the ordinary course of performing my duties as an employee of the Company. 

2. I agree that, during the period of my employment by the Company, I will not, without the Company’s express prior written consent, engage in any
employment or consulting other than for the Company. In the event of the termination of my employment by me or by the Company for any reason, I will promptly deliver to the Company all documents and data of any nature pertaining to my work with the
Company and I will not take with me any documents or data of any description or any reproduction of any description containing or pertaining to any Proprietary Information. 

 Mrs. Alane Barnes 

August 1, 2013 
  Page
 10
 
  

 3. I will promptly and fully disclose to the Company, or any persons designated by it, all improvements,
inventions, formulas, processes, techniques, know-how, and data, whether or not patentable, copyrightable, or otherwise protectible as property, made or conceived or reduced to practice or learned by me, either alone or jointly with others, during
the period of my employment by the Company which are related to or useful in the business of the Company, or result from tasks assigned me by the Company or result from use of premises owned, leased, or contracted for by the Company (all said
improvements, inventions, formulas, processes, techniques, know-how, and data shall be collectively hereinafter called “Inventions”). I agree to keep complete, accurate, and authentic accounts, notes, data, and records of all Inventions in
the manner and form requested by the Company, which accounts, notes, data, and records shall be and remain the sole property of the Company. I agree to surrender the same promptly to the Company upon its request or, in the absence of such a request,
upon the termination of my employment by the Company. 
 4. I agree that all Inventions are and shall be the sole property of the Company and its assigns,
and that the Company and its assigns shall be the sole owner of all patents and other rights in connection therewith. I hereby assign to the Company any and all rights I may have or acquire in or to such Inventions and patents. I further agree as to
all such Inventions to assist the Company in every proper way (but at the Company’s expense) to obtain and from time to time enforce patents, including amendments, extensions, and continuations of said patents on said Inventions in any and all
countries, and to that end I will execute all documents for use in applying for and for obtaining such patents, amendments, extensions, and continuations and enforcing same, as the Company may desire, together with any assignments thereof to the
Company or persons designated by it. My obligation to assist the Company in obtaining and enforcing patents, amendments, extensions, and continuations for such Inventions in any and all countries shall continue beyond the termination of my
employment, but the Company shall compensate me at a reasonable rate after such termination for time actually spent by me at the Company’s request on such assistance. 

5. As a matter of record I attach hereto a complete list of all Inventions or improvements relevant to the subject matter of my employment by the Company
which have been conceived, made, or reduced to practice by me, alone or jointly with others, prior to my engagement by the Company which I desire to remove from the operation of this Agreement. I covenant that such list is complete. If no such list
is attached to this Agreement, I represent that I have no such Inventions and improvements at the time of signing this Agreement. 
 6. I represent that my
performance of all of the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence Proprietary Information acquired by me in confidence or in trust prior to my employment by the
Company. I have not entered into, and I agree that I will not enter into, any agreement either written or oral, in conflict herewith. 
 7. I understand
that, as part of the consideration of the offer of employment extended to me by the Company or of my continued employment by the Company, as the case may be, I will not bring, have not brought, with me to the Company and I will not use, have not
used, in the performance of my responsibilities at the Company, materials or documents of a former employer, unless I have obtained written authorization from the former employer for their possession and use. Accordingly, this is to advise the
Company that the only materials that I will bring to the Company or use in my employment are identified on the attached sheet (Exhibit A) and, as to each such item, I represent that I have obtained, prior to the effective date of my employment with
the Company, written authorization for their possession and use in my employment with the Company. I also understand that, in my employment with the Company. I am not to breach any obligation of confidentiality that I have to former employers, and I
agree that I shall fulfill all such obligations during my employment with the Company. 

 Mrs. Alane Barnes 

August 1, 2013 
  Page
 11
 
  

 8. This Agreement shall be effective as of the first day of my employment by the Company, namely: September
8, 2006. I understand and agree that this Agreement is not a contract of employment and that my employment by the Company is, for all purposes, “at will.” 

9. This Agreement shall be binding upon me, my heirs, executors, assigns, administrators, and other legal representatives and shall inure to the benefit of
the Company, its successors and assigns. 
  

									
	DATED:	 	  
	 		 	Employee:	 	  

				
	ACCEPTED AND AGREED TO:	 		 		 	
				
	BIOCRYST PHARMACEUTICALS, INC.	 		 		 	
					
	BY:	 	  
	 		 		 	
	AS ITS: Vice President of Human Resources	 		 		 	
					
	Dated:	 	  
	 		 		 	
				
	BioCryst Pharmaceuticals, Inc.	 		 		 	
	4505 Emperor Blvd., Suite 200	 		 		 	
	Durham, NC 27703	 		 		 	

 Dear Sir: 
 I
                    propose to bring to my BioCryst employment the following tangible materials and previously unpublished documents, which materials
and documents may be used in my BioCryst employment: 
  

					
	     No materials	  	    See below	  	    Additional sheets attached

 The signature below by a representative of my current or former employer confirms that my continued possession and use of
these materials is authorized. 
  

			
	AUTHORIZATION:
	
	  

	Signature
	Title:	 	  

	
	  

	Employer

  

	
	  

	EmployeeEX-10.23

 Exhibit 10.23 
  

 
 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE 
PAGE OF PAGES 1 | 2 
2. MODIFICATION NO: 
013 
3. EFFECTIVE DATE 
See block 16C 
4. REQUISITION/PURC 
N/A 
5. PROJECT NO. (If applicable) 
N/A 
6. ISSUED BY CODE 
Biomedical Advanced Research and Development Authority U.S. Department of
Health and Human Services 330 Independence Avenue, SW Room G640 Washington, DC 20201 
7. ADMINISTERED BY (If other than Item 6) CODE 
8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) 
BioCryst
Pharmaceuticals, Inc. 
4505 Emperor Boulevard, Suite 200 
Durham, NC 27703

DUNS 61-819-4609 
TIN 62-1413174 
9A. AMENDMENT OF SOLICITATION NO. 
9B. DATED (SEE ITEM 11) 
10A.MODIFICATION OF CONTRACT/ ORDER 
X 
HHS0100200700032C 
10B. DATED (SEE ITEM 13) 
01-03-07 
CODE 
FACILITY CODE 
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS 
~ The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers ~ is extended, ~ is not extended. 
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing
Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment
numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment, you desire to change an offer
already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. 
12. ACCOUNTING AND APPROPRIATION DATA (If required) 
SOCC: DOC# TIN# LOC# CAN# 
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS; IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 
14. THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

X 
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: 
FAR 52.243-2 (Aug ’87) Changes–Cost Reimbursement, Alternate V (Apr. 1984) 
B. THE
ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying 
office, appropriation date, etc.) SET FORTH IN ITEM 14,
PURSUANT TO THE AUTHORITY OF FAR 43.103(b). 
C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: 
D. OTHER (Specify type of modification and authority) 
E. IMPORTANT: Contractor [] is not, [X]
is required to sign this document and return 2 copies to the issuing office. 
14. DESCRIPTION OF MODIFICATION (Organized by UCF section headings, including
solicitation/contract subject matter where feasible) 
PURPOSE: The purpose of this modification is to: 
1. Incorporate Advanced Understandings to transfer 240 vials of peramivir to BioCryst 
2. Add
and exercise Optional CLIN 0009 to include 84-month stability testing. 
The total contract amount remains unchanged at $234,852,147. 
The contract completion date remains unchanged at December 31, 2013. 
Except as provided
herein, all terms and conditions referenced in item 9A or 10A, remain in full force and effect. 
15A. NAME AND TITLE OF SIGNER (Type or print) 
Jon P. Stonehouse 
President & CEO 
15B. CONTRACTOR/OFFEROR 
(Signature of person authorized to sign) 
15C. DATE SIGNED 
2-15-12 
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) 
VIJAYA L. MURTHY, CONTRACTING
OFFICER 
16B. UNITED STATES OF AMERICA 
BY Vijaya L. Murty 
(Signature of Contracting Officer) 
16C. DATE SIGNED 
2/15/12 
NSN 7540-01-152-8070 
OMB No. 0990—0115 
STANDARD FORM 30 (REV. 10-83) 
HHS0100200700032C 

 Modification # 013 

Page 2 of 2 
  

	1.	ARTICLE B.6 ADVANCED UNDERSTANDING is modified to add the following: 

 “ARTICLE B.6.5. 

The government will provide to the contractor 240 vials (16 treatment courses at 15 vials per treatment course) of peramivir from lot C0307
that is currently stored at the Supply Service Center at Perry Point, MD. This transfer will be initiated by BioCryst in the form of a written request to the Contracting Officer and will be coordinated with the Project Officer.” 

 

	2.	This modification adds to the contract and exercises Optional CLIN 0009. 

 The funding for
Optional CLIN 0009 is included in CLIN 0004-Contractor-defined Milestones. The testing will be performed in conformance with FDA requirements beyond the period of performance of this contract. 

Except as otherwise provided herein, this modification caps the period of performance for Optional CLIN 0009 at the expiration date of this
contract, December 31, 2013. A formal extension to cover the 84-month period must be requested by BioCryst at least 60 days before December 31, 2013, to extend the period of performance. 

 

									
	 CLIN
	  	 Supplies/Services
	  	 Quantity/Unit
	  	Price	 
	 Optional
 CLIN

0009
	  	 The Contractor shall perform additional stability extension services for Peramivir IV supplies currently being held at the Supply
Service Center at Perry Point, MD, extending the shelf life to 84 months in conformance with FDA requirements.
	  	84 month period of performance	  	$
  
	119,311
 (FFP
	  
 ) 

  

	3.	All other terms and conditions of the contract remain unchanged.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]